Microglia-Derived Extracellular Vesicle Engineering for Targeted Mitochondrial Delivery
Target: RAB27A/LAMP2B
Composite Score: 0.482
Price: $0.48▲64.7%
Citation Quality: Pending
neurodegeneration
Status: proposed
🟢 Parkinson's Disease 🔮 Lysosomal / Autophagy 🔥 Neuroinflammation 🔴 Alzheimer's Disease 🟡 ALS / Motor Neuron Disease 🧠 Neurodegeneration
✓ All Quality Gates Passed
Quality Report Card click to collapse
C
Composite: 0.482
Top 78% of 1402 hypotheses
T5 Contested
Contradicted by evidence, under dispute
F
0.20
Top 99%
D
0.30
Top 91%
A
0.80
Top 25%
D
0.30
Top 90%
B+
0.70
Top 42%
C
0.40
Top 78%
D
0.30
Top 92%
B
0.60
Top 61%
C
0.40
Top 87%
D
0.30
Top 94%
Evidence
3 supporting
|
3 opposing
Citation quality: 100%
Debates
1 session
A
Avg quality: 0.81
Convergence
1.00
A+
30 related hypothesis share this target
From Analysis:
Mitochondrial transfer between neurons and glia
What are the mechanisms underlying mitochondrial transfer between neurons and glia?
Hypotheses from Same Analysis (6)
These hypotheses emerged from the same multi-agent debate that produced this hypothesis.
Astrocytic Connexin-43 Upregulation Enhances Neuroprotective Mitochondrial Donation
Score: 0.559 | Target: GJA1
Miro1-Mediated Mitochondrial Trafficking Enhancement Therapy
Score: 0.549 | Target: RHOT1
PINK1/Parkin-Independent Mitophagy Bypass for Enhanced Donor Mitochondria
Score: 0.529 | Target: BNIP3/BNIP3L
Synthetic Biology Approach: Designer Mitochondrial Export Systems
Score: 0.505 | Target: Synthetic fusion proteins
Optogenetic Control of Mitochondrial Transfer Networks
Score: 0.476 | Target: ChR2
Gap Junction Hemichannel Modulation for Controlled Mitochondrial Exchange
Score: 0.436 | Target: PANX1
Description
Genetically modified microglia overexpressing mitochondrial export machinery package healthy mitochondria into extracellular vesicles with neuron-specific targeting ligands.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
graph TD
A["Microglia"] --> B["Natural EV Secretion"]
B --> C["Extracellular Vesicles"]
D["Engineering EVs"] --> E["RAB27A Overexpression"]
E --> F["Enhanced EV Production"]
D --> G["LAMP2B Surface Targeting"]
G --> H["Neuron-Specific Ligands"]
H --> I["Targeted EV Delivery"]
D --> J["Load Healthy Mitochondria"]
J --> K["Mito-Enriched EVs"]
F --> L["Engineered Microglia-EVs"]
I --> L
K --> L
L --> M["Targeted Delivery to Damaged Neurons"]
N["Damaged Neurons"] --> O["Mitochondrial Dysfunction"]
O --> P["Energy Failure"]
M --> Q["Mito Integration into Neurons"]
Q --> R["Restored Bioenergetics"]
R --> S["Neuronal Rescue"]
T["Advantages"] --> U["Cross BBB via EVs"]
T --> V["Cell-Type-Specific Targeting"]
T --> W["Scalable Production"]
S --> X["Targeted Mitochondrial Therapy"]
style A fill:#264653,stroke:#ffd54f,color:#e0e0e0
style D fill:#1a3a4a,stroke:#4fc3f7,color:#e0e0e0
style M fill:#1a3a2a,stroke:#81c784,color:#e0e0e0
style X fill:#2a3a1a,stroke:#c5e1a5,color:#e0e0e0
3D Protein Structure (AlphaFold)
Open full viewerAlphaFold predicted structure available for P13473
View AlphaFold StructureDimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
6 citations
6 with PMID
Validation: 100%
3 supporting / 3 opposing
✓
For
(3)
(3)
Against
✗
High
Medium
Low
High
Medium
Low
Evidence Matrix
— sortable by strength/year, click Abstract to expand
Evidence Types
MECH 6CLIN 0GENE 0EPID 0
Legacy Card View — expandable citation cards
✓ Supporting Evidence 3
Microglia release mitochondria-containing extracellular vesicles that can rescue neuronal function
RAB27A regulates mitochondrial trafficking into extracellular vesicles
LAMP2B-based targeting vectors enable neuron-specific delivery
✗ Opposing Evidence 3
Most mitochondria-containing extracellular vesicles actually contain mitochondrial fragments or DNA, not intac…▼
Most mitochondria-containing extracellular vesicles actually contain mitochondrial fragments or DNA, not intact functional organelles
Systemically delivered LAMP2B-targeted vesicles show <1% brain uptake and poor neuronal specificity
Microglial activation states critically determine vesicle content, with pro-inflammatory microglia releasing d…▼
Microglial activation states critically determine vesicle content, with pro-inflammatory microglia releasing damaging rather than protective cargo
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 5 rounds | 2026-04-01 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼
Novel Therapeutic Hypotheses for Mitochondrial Transfer in Neurodegeneration
Hypothesis 1: Astrocytic Connexin-43 Upregulation Enhances Neuroprotective Mitochondrial Donation
Description: Pharmacological enhancement of connexin-43 expression in astrocytes increases tunneling nanotube formation and mitochondrial transfer to damaged neurons. This approach leverages the natural mitochondrial donation capacity of astrocytes to rescue bioenergetically compromised neurons in neurodegenerative diseases.
Target: Connexin-43 (GJA1 gene)
Supporting Evidence: Astrocytes transfer func
🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼
Critical Evaluation of Mitochondrial Transfer Hypotheses
Hypothesis 1: Astrocytic Connexin-43 Upregulation
Specific Weaknesses:
- Confounded mechanism: Connexin-43 primarily forms gap junctions for small molecule exchange, not structural tunneling nanotubes for organelle transfer
- Oversimplified pathway: The evidence conflates gap junction communication with physical mitochondrial transfer mechanisms
- Limited therapeutic window: Connexin-43 upregulation could cause seizures and cardiac arrhythmias due to excessive gap junction coupling
Counter-Evidence:
- Connexin
🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼
Practical Feasibility Assessment of Mitochondrial Transfer Hypotheses
Executive Summary
After critical analysis, most hypotheses face significant technical and commercial barriers. Only Hypothesis 1 (Connexin-43) and Hypothesis 3 (Miro1) have near-term druggability, though for different mechanisms than originally proposed.
Hypothesis 1: Astrocytic Connexin-43 Upregulation
Revised Mechanism: Enhanced gap junction-mediated metabolic coupling rather than direct mitochondrial transferDruggability Assessment: MODERATE
Target: Connexin-43 (GJA1) - established⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼
Price History
7d Trend
↔
Stable
7d Momentum
▼ 0.6%
Volatility
Low
0.0118
Events (7d)
6
⚡ Price Movement Log
Recent 15 events
| Event | Price | Change | Source | Time | |
|---|---|---|---|---|---|
| 📄 | New Evidence | $0.397 | ▲ 1.5% | evidence_batch_update | 2026-04-13 02:18 |
| 📄 | New Evidence | $0.391 | ▲ 5.7% | evidence_batch_update | 2026-04-13 02:18 |
| ⚖ | Recalibrated | $0.370 | ▼ 1.5% | 2026-04-10 15:58 | |
| ⚖ | Recalibrated | $0.376 | ▲ 1.8% | 2026-04-10 15:53 | |
| ⚖ | Recalibrated | $0.369 | ▲ 0.3% | 2026-04-08 18:39 | |
| ⚖ | Recalibrated | $0.368 | ▼ 0.9% | 2026-04-04 16:38 | |
| ⚖ | Recalibrated | $0.371 | ▼ 2.0% | 2026-04-04 16:02 | |
| 📄 | New Evidence | $0.379 | ▲ 2.4% | evidence_batch_update | 2026-04-04 09:08 |
| ⚖ | Recalibrated | $0.370 | ▼ 29.0% | 2026-04-03 23:46 | |
| 💬 | Debate Round | $0.521 | ▲ 15.6% | market_dynamics | 2026-04-03 09:22 |
| 💬 | Debate Round | $0.451 | ▼ 13.5% | market_dynamics | 2026-04-03 07:27 |
| 💬 | Debate Round | $0.521 | ▲ 24.6% | market_dynamics | 2026-04-03 07:15 |
| 💬 | Debate Round | $0.418 | ▼ 21.1% | market_dynamics | 2026-04-03 05:25 |
| 📊 | Score Update | $0.530 | ▲ 1.6% | market_dynamics | 2026-04-03 05:10 |
| 📄 | New Evidence | $0.521 | ▲ 18.5% | market_dynamics | 2026-04-03 04:12 |
Clinical Trials (5) Relevance: 38%
0
Active
Active
0
Completed
Completed
1,240
Total Enrolled
Total Enrolled
PHASE1
Highest Phase
Highest Phase
UNKNOWN
·
NCT04887675 · University of Novi Sad
120 enrolled · 2021-05-01 · → 2022-06-01
Since the HIV changed its course to the chronic disease, high incidence of metabolic syndrome both in HIV positive and negative subjects has become an issue. Given the successful peripheral suppressio
HIV I Infection HIV Associated Lipodystrophy Metabolic Syndrome
MRI
ENROLLING_BY_INVITATION
·
NCT06875739 · Fondazione Don Carlo Gnocchi Onlus
310 enrolled · 2025-02-14 · → 2026-10-01
The aim of the study is to validate a salivary test that allows for rapid and accurate objective diagnosis in the context of neurodegenerative diseases, a complex of diseases that includes Alzheimer's
Neurodegenerative Disorders Parkinson Disease Alzheimer Disease
RECRUITING
·
NCT00029965 · National Human Genome Research Institute (NHGRI)
200 enrolled · 2002-02-06
Study description:
This is a natural history study that will evaluate any patient with enzyme or DNA confirmed GM1 or GM2 gangliosidosis, sialidosis or galactosialidosis. Patients may be evaluated ev
Neurological Regression Myoclonus Cherry Red Spot
COMPLETED
·
NCT04281186 · Hospital Universitari Vall d'Hebron Research Institute
510 enrolled · 2020-11-16 · → 2024-12-12
The retina shares similar embryologic origin, anatomical features and physiological properties with the brain and hence offers a unique and accessible "window" to study the correlates and consequences
Retinal Function Cognitive Dysfunction Microperimetry
UNKNOWN
·
NCT04248270 · Chang Gung Memorial Hospital
100 enrolled · 2020-02-20 · → 2023-08-17
Dementia is a clinical syndrome which characterized by progressive cognitive impairment, behavior disturbance and dysfunction of daily activity. In aging population, Alzheimer's dementia (AD) is the m
Alzheimer's Disease Vascular Dementia Dementia
18F-PM-PBB3
📚 Cited Papers (36)
Predictive Role of High Blood Pressure for the Incidence of Metabolic Syndrome.
Cardiology (2019) · PMID:31261156
1 figure
Figures
Figures available at source paper (no open-access XML found).
deep_link
Adapting Drosophila melanogaster Cell Lines to Serum-Free Culture Conditions.
G3 (Bethesda, Md.) (2020) · PMID:33028628
5 figures
Figure 1
Adapting Drosophila S2R+ cells to FEx supplemented media. S2R+ cells were gradually adapted from M3 + BPYE + 10% FBS (MB10) into M3 + 10% FEx and M3 + 2.5% FEx. Transcriptomic an...
pmc_api
Figure 3
Differential gene expression in S2R+ cultures across three culture conditions. (A) Volcano plot of differentially expressed genes from comparison of cells cultured in M3 + 2.5% FEx...
pmc_api
Brain Photobiomodulation Therapy: a Narrative Review.
Molecular neurobiology (2018) · PMID:29327206
1 figure
Figures
Figures available at source paper (no open-access XML found).
deep_link
Metformin use and risk of gastric adenocarcinoma in a Swedish population-based cohort study.
British journal of cancer (2019) · PMID:31591459
1 figure
Figures
Figures available at source paper (no open-access XML found).
deep_link
Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions.
Nature biotechnology (2017) · PMID:28319085
No extracted figures yet
Brain Photobiomodulation Therapy: a Narrative Review.
Molecular neurobiology (2018) · PMID:29327206
No extracted figures yet
The Science and Translation of Lactate Shuttle Theory.
Cell metabolism (2018) · PMID:29617642
No extracted figures yet
Aiming for the target: Mitochondrial drug delivery in traumatic brain injury.
Neuropharmacology (2019) · PMID:30009835
No extracted figures yet
A transgenic inducible GFP extracellular-vesicle reporter (TIGER) mouse illuminates neonatal cortical astrocytes as a source of immunomodulatory extracellular vesicles.
Scientific reports (2019) · PMID:30816224
No extracted figures yet
Predictive Role of High Blood Pressure for the Incidence of Metabolic Syndrome.
Cardiology (2019) · PMID:31261156
No extracted figures yet
Separating out the middle.
Nature materials (2020) · PMID:31308518
No extracted figures yet
Metformin use and risk of gastric adenocarcinoma in a Swedish population-based cohort study.
British journal of cancer (2019) · PMID:31591459
No extracted figures yet
📙 Related Wiki Pages (15)
Mitochondrial Biogenesis Inducers therapeuticSection 138: Advanced Extracellular Matrix and Int therapeuticiPSC-Derived Neurons for Drug Screening in CBS/PSP therapeuticMitochondrial Dynamics Modulators for Neurodegener therapeuticMitochondrial Support Strategies for CBS/PSP therapeuticSection 194: Advanced Membrane Trafficking and Ves therapeuticBBB-Penetrant Antibody Engineering therapeuticAAV Gene Therapy for Neurodevelopmental Epilepsy — therapeuticExosome-Based Drug Delivery for CBS/PSP therapeuticGlial Cell Line-Derived Neurotrophic Factor (GDNF) therapeuticRAB27A Gene geneRAB27A Protein (Ras-Related Protein Rab-27A) proteinExtracellular Vesicle-Mediated Synuclein Propagati hypothesisAutologous Stem Cell-Derived Dopaminergic Neurons clinicalExtracellular Vesicle-Based Neuroprotective Therap idea
📓 Linked Notebooks (7)
📓 Top 5 Analysis: Sda 2026 04 01 Gap 20260401231108
Computational notebook for SDA-2026-04-01-gap-20260401231108
📓 SciDEX Analysis: 2026 04 01 Gap 20260401231108
Computational notebook for SDA-2026-04-01-gap-20260401231108
📓 Mitochondrial transfer between neurons and glia — Analysis Notebook
Jupyter notebook for analysis SDA-2026-04-01-gap-20260401231108: What are the mechanisms underlying mitochondrial transfer between neurons and glia?
📓 Mitochondrial transfer between neurons and glia — Rich Analysis Notebook
Comprehensive analysis with gene expression, pathway enrichment, and statistical tests for Mitochondrial transfer between neurons and glia
📓 Mitochondrial transfer between neurons and glia — Analysis Notebook
Jupyter notebook for analysis SDA-2026-04-01-gap-20260401231108: What are the mechanisms underlying mitochondrial transfer between neurons and glia?
📓 Mitochondrial transfer between neurons and glia
Analysis ID: SDA-2026-04-01-gap-20260401231108
📓 Mitochondrial transfer between neurons and glia
Analysis ID: SDA-2026-04-01-gap-20260401231108
Date: 2026-04-02
Domain: neurodegeneration
Hypotheses Generated: 7
Knowledge Graph Edges: 0
📊 Resource Economics & ROI
Moderate Efficiency
Resource Efficiency Score
0.59
34.1th percentile (747 hypotheses)
Tokens Used
5,460
KG Edges Generated
13
Citations Produced
15
Cost Ratios
Cost per KG Edge
80.29 tokens
Lower is better (baseline: 2000)
Cost per Citation
780.00 tokens
Lower is better (baseline: 1000)
Cost per Score Point
11188.52 tokens
Tokens / composite_score
Score Impact
Efficiency Boost to Composite
+0.059
10% weight of efficiency score
Adjusted Composite
0.541
How Economics Pricing Works
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
Efficiency Price Signals
| Date | Signal Price | Score |
|---|---|---|
| 2026-04-16T20:00 | $0.386 | 0.510 |
Wiki Pages
Mitochondrial Biogenesis InducerstherapeuticSection 138: Advanced Extracellular Matrix and InttherapeuticiPSC-Derived Neurons for Drug Screening in CBS/PSPtherapeuticMitochondrial Dynamics Modulators for NeurodegenertherapeuticMitochondrial Support Strategies for CBS/PSPtherapeuticSection 194: Advanced Membrane Trafficking and VestherapeuticBBB-Penetrant Antibody EngineeringtherapeuticAAV Gene Therapy for Neurodevelopmental Epilepsy —therapeuticExosome-Based Drug Delivery for CBS/PSPtherapeuticGlial Cell Line-Derived Neurotrophic Factor (GDNF)therapeuticRAB27A GenegeneRAB27A Protein (Ras-Related Protein Rab-27A)proteinExtracellular Vesicle-Mediated Synuclein PropagatihypothesisAutologous Stem Cell-Derived Dopaminergic Neurons clinicalExtracellular Vesicle-Based Neuroprotective Therapidea
Related Hypotheses
LPS-TLR4-NF-κB Signaling Cascade as Therapeutic Target
Score: 7.200 | neurodegeneration
Enteric Nervous System Dysfunction as Self-Reinforcing Pathological Loop
Score: 7.000 | neurodegeneration
Vagus Nerve as Anatomical Highway for Prion-Like α-Syn Propagation
Score: 6.000 | neurodegeneration
SCFA Deficiency Disrupts Microglial Homeostasis and Promotes Neurodegeneration
Score: 5.500 | neurodegeneration
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration
Score: 0.990 | neurodegeneration
Estimated Development
Estimated Cost
$0
Timeline
2.5 years
🧪 Falsifiable Predictions (4)
4 total
0 confirmed
0 falsified
If hypothesis is true, intervention involve primary microglia or immortalized microglial cell lines (BV2, N9) transfected with lentiviral vectors expressing RAB27A and LAMP2B-RVG fusion proteins
pending
conf: 0.30
Expected outcome: involve primary microglia or immortalized microglial cell lines (BV2, N9) transfected with lentiviral vectors expressing RAB27A and LAMP2B-RVG fusion proteins
Falsified by: Intervention fails to involve primary microglia or immortalized microglial cell lines (BV2, N9) transfected with lentiviral vectors expressing RAB27A and LAMP2B-RVG fusion proteins
If hypothesis is true, intervention be assessed using MitoTracker dyes and electron microscopy of isolated EVs
pending
conf: 0.30
Expected outcome: be assessed using MitoTracker dyes and electron microscopy of isolated EVs
Falsified by: Intervention fails to be assessed using MitoTracker dyes and electron microscopy of isolated EVs
If hypothesis is true, intervention restore neuronal bioenergetics in neurodegenerative conditions
pending
conf: 0.30
Expected outcome: restore neuronal bioenergetics in neurodegenerative conditions
Falsified by: Intervention fails to restore neuronal bioenergetics in neurodegenerative conditions
If hypothesis is true, intervention rescue bioenergetic deficits in Parkinson's disease models
pending
conf: 0.30
Expected outcome: rescue bioenergetic deficits in Parkinson's disease models
Falsified by: Intervention fails to rescue bioenergetic deficits in Parkinson's disease models
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
Predicted Protein Structure
🔮 RAB27A — AlphaFold Prediction P51159 Click to expand 3D viewer
Source Analysis
Mitochondrial transfer between neurons and glia
neurodegeneration | 2026-04-01 | completed
Community Feedback
0
0 upvotes · 0 downvotes
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!